Premium
Effects of crocin in reducing DNA damage, inflammation, and oxidative stress in multiple sclerosis patients: A double‐blind, randomized, and placebo‐controlled trial
Author(s) -
Ghiasian Masoud,
Khamisabadi Forough,
Kheiripour Nejat,
Karami Manouchehr,
Haddadi Rasool,
Ghaleiha Ali,
Taghvaei Babak,
Oliaie Seyed Sajad,
Salehi Mohammadjavad,
Samadi Pouria,
Ranjbar Akram
Publication year - 2019
Publication title -
journal of biochemical and molecular toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.526
H-Index - 58
eISSN - 1099-0461
pISSN - 1095-6670
DOI - 10.1002/jbt.22410
Subject(s) - crocin , oxidative stress , placebo , medicine , multiple sclerosis , lipid peroxidation , dna damage , pharmacology , inflammation , immunology , gastroenterology , pathology , chemistry , biochemistry , dna , alternative medicine
Abstract Multiple sclerosis (MS) is an autoimmune disease in which the immune system attacks the nerve cells, resulting in neurological disorders. Oxidative stress, free radicals, and neuritis have important roles in MS pathogenesis. Here, we aim to evaluate the effect of crocin on inflammatory markers, oxidative damage, and deoxyribonucleic acid (DNA) damage in the blood of patients with MS. A total of 40 patients were divided into two groups, drug and placebo‐treated groups, using random assignment. Participants of the intervention and control groups received two crocin capsules or placebo per day for 28 days, respectively. Findings revealed a significant decrease in the level of important pathogenic factors in MS, including lipid peroxidation, DNA damage, tumor necrosis factor‐alpha, and interleukin 17 as well as a significant increase in the total antioxidant capacity in the serum of patients treated with crocin compared with the placebo group. Our results suggest the beneficial and therapeutic effects of crocin in MS.